Pallas Capital Advisors LLC Purchases 32,996 Shares of 10x Genomics $TXG

Key Points

• Pallas Capital Advisors LLC increased its stake in 10x Genomics by 138.8%, acquiring an additional 32,996 shares valued at approximately $657,000.
• 10x Genomics reported a 12.9% increase in quarterly revenue, totaling $172.91 million, and exceeded earnings expectations with $0.28 EPS compared to an estimate of ($0.35).
• Institutional investors collectively own 84.68% of 10x Genomics' stock, indicating significant market confidence in the company.

Pallas Capital Advisors LLC grew its holdings in 10x Genomics (NASDAQ:TXG - Free Report) by 138.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 56,776 shares of the company's stock after acquiring an additional 32,996 shares during the quarter. Pallas Capital Advisors LLC's holdings in 10x Genomics were worth $657,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC increased its stake in shares of 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after buying an additional 1,614 shares during the period. Amundi lifted its holdings in shares of 10x Genomics by 16,013.7% in the 1st quarter. Amundi now owns 320,340 shares of the company's stock worth $2,553,000 after purchasing an additional 318,352 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of 10x Genomics by 235.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock worth $62,016,000 after purchasing an additional 4,987,195 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in 10x Genomics by 163.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company's stock valued at $5,634,000 after acquiring an additional 400,430 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in 10x Genomics by 35.3% during the 4th quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock valued at $146,000 after acquiring an additional 2,657 shares in the last quarter. Institutional investors own 84.68% of the company's stock.

Insider Buying and Selling at 10x Genomics

In other news, CEO Serge Saxonov sold 9,348 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the sale, the chief executive officer owned 945,892 shares in the company, valued at $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Adam Taich sold 22,315 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the transaction, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. This trade represents a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,149 shares of company stock worth $539,865. 10.03% of the stock is owned by insiders.

10x Genomics Stock Performance

Shares of 10x Genomics stock traded down $0.17 during trading hours on Tuesday, hitting $12.87. The company's stock had a trading volume of 101,775 shares, compared to its average volume of 3,283,192. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -18.40 and a beta of 2.00. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $23.16. The firm has a fifty day moving average of $13.30 and a 200-day moving average of $10.90.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.63. The business had revenue of $172.91 million during the quarter, compared to analysts' expectations of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business's quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, sell-side analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on TXG. Bank of America lifted their price objective on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, June 26th. Zacks Research downgraded 10x Genomics from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 5th. Morgan Stanley dropped their target price on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Tuesday, August 12th. UBS Group lifted their price target on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday, September 13th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $13.65.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.